bioAffinity Technologies (NASDAQ:BIAF) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of bioAffinity Technologies (NASDAQ:BIAF) from a hold rating to a sell rating in a research note published on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

bioAffinity Technologies Stock Down 7.1%

BIAF opened at $0.56 on Friday. The stock has a market cap of $2.63 million, a PE ratio of -0.05 and a beta of -1.05. The company has a quick ratio of 1.34, a current ratio of 1.36 and a debt-to-equity ratio of 0.15. bioAffinity Technologies has a 52 week low of $0.55 and a 52 week high of $13.50. The business’s fifty day simple moving average is $1.00 and its 200 day simple moving average is $1.66.

bioAffinity Technologies (NASDAQ:BIAF) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.40) by $1.59. The firm had revenue of $1.35 million during the quarter, compared to analyst estimates of $1.48 million. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.

Institutional Trading of bioAffinity Technologies

Several large investors have recently modified their holdings of the business. J. Safra Sarasin Holding AG bought a new position in bioAffinity Technologies during the 1st quarter valued at approximately $164,000. Geode Capital Management LLC bought a new stake in shares of bioAffinity Technologies in the 4th quarter worth approximately $36,000. Finally, Scientech Research LLC bought a new stake in shares of bioAffinity Technologies in the 3rd quarter worth approximately $49,000. 1.64% of the stock is owned by institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.